|
KEY: CR = Complete Response | Tx = Treatment | m =
Maintenance | x4 = 4 rounds |
TTP = Time to Progression | Mng = Management | D = durable remission / cure |
|
Options for follicular
NHL
|
Goal
of Tx
|
TTP/EFS
mo
|
Response
notes |
Notes |
Related
articles
|
| Prednisone |
Mng |
|
fast acting |
toxicity with
extended use |
articles |
|
|
|
|
|
|
| Rituxan x4 |
Mng |
TTP
12 |
54%; 14 pts 36%
stable or minor response |
More specific,
less toxic than
chemo; effect on overall
survival unknown |
articles |
| Rituxan x4 / x8 /m |
Mng |
TTP
34 |
56% (8% CR). |
while promising,
affect on overall
survival is unknown |
articles |
| Rituxan x4 / x8 |
Mng |
EFS
36 |
Event-free survival
(EFS) was 12 months in the no further treatment arm vs. 23
months in the prolonged treatment arm (p=0.02), the difference
being particularly notable in chemotherapy-naive patients (19
vs. 36 months, p=0.009) and in patients responding to
induction treatment (16 vs. 36 months, p=0.004). |
|
Blood. 2004 Feb 19
PMID: 14976046
articles |
| Rituxan + gm-csf x4/x8/m |
Mng |
- |
20 patients with
relapsed disease, the combination of granulocyte-colony
stimulating factor with rituximab resulted in a longer
duration of response than normally seen with rituximab
monotherapy. - Kimby |
|
articles |
| Rituxan + IL-2 |
Mng |
- |
|
|
articles |
| Rituxan + Prednisone |
Mng |
- |
|
|
articles |
| Rituxan + Interferon-alpha |
Mng |
TTP
22.3
and 25.2 |
Data for relapsed
setting. |
INF-alpha can cause
unpleasant side effects. |
articles |
| Rituxan + Pentostatin |
Mng |
TTP
15 |
77% responded - 22.3% CR;
Previously untreated vs previously
treated pts was 83% vs 63% |
|
articles |
| Rituxan + Fludarabine |
|
|
|
|
|
|
|
|
|
|
articles |
| Radiotherapy, localized |
D |
|
For stage I and II
can
be curative (C) |
surviving patients
ranged from
3.5 to 28.7 years (median 19.0) |
articles |
|
|
|
|
|
articles |
| Chlorambucil |
Mng |
|
|
|
articles |
| Fludarabine |
D |
|
Fludarabine,
cyclophosphamide and mitoxantrone for untreated follicular
lymphoma: a report from the non-Hodgkin's lymphoma
co-operative study group. Leuk Lymphoma. 2004
Jun;45(6):1141-7. PMID:
15359993 | |
|
Related
articles |
| CVP / COP |
Mng/D |
|
|
|
articles |
Combination chemo
with adjuvant radiotherapy
to bulky nodes |
D |
|
71% survival at 20
years for
pts with advanced disease |
Intriguing report,
Some experts
question methodology. |
articles |
|
|
|
|
|
related articles |
|
CVP + Rituxan |
D |
TTP
32 |
CVP chemotherapy
plus Rituximab compared with CVP as first-line treatment for
advanced follicular lymphoma. [322 patient study] Blood.
2004 Oct 19 PMID:
15494430 | |
Overall and complete
response rates were
81% and 41% in the R-CVP arm vs. 57% and 10% in the CVP
arm, respectively (P < 0.0001). Median Time to
progression: 32 months vs. 15 months for CVP; P < 0.0001). |
Related
articles
|
| Chlorambucil + Rituxan |
Mng |
|
|
(PMID:
14531908) |
articles |
Rituxan > Chlorambucil
(added if needed) |
Mng |
|
|
|
none |
|
MC + Rituxan |
D |
TTP
30 |
|
PMID: 14579238 |
articles |
|
FCM + Rituxan |
D |
|
|
PMID: 12652460 |
articles |
|
CNOP + Rituxan |
D |
|
|
PMID: 12750729 |
articles |
|
FND + Rituxan |
D |
|
|
PMID: 11225999 |
articles |
|
CHOP + Rituxan |
D |
TTP
82 |
Prolonged Clinical
and Molecular Remission in Patients With Low-Grade or
Follicular Non-Hodgkin's Lymphoma Treated With Rituximab Plus
CHOP Chemotherapy: 9-Year Follow-Up. J Clin Oncol. 2004 Oct 13 |
|
articles |
|
|
|
|
|
|
|
Rituxan > FavId vaccine |
Mng/D |
|
|
|
articles |
CVP > vaccine vs.
CVP > control |
D |
|
|
|
articles |
|
CHOP+Bexxar vs. CHOP+Rituxan |
D |
|
|
|
articles |
| F is Fludarabine
| M/N is Mitoxantrone | C is Cyclophosphamide | D is Dexamethasone
| V/O is Vincristine | P is Prednisone | H is Doxorubicin |
